Driving a step change in the treatment of cancer
Dencatistat is a first-in-class, oral, highly selective inhibitor of CTPS1, the enzyme cancer cells rely on to copy their DNA.
One enzyme, one bottleneck
- Activated T cells need CTPTo divide, lymphocytes must build new DNA. The rate limiting step is CTPS1 turning UTP into CTP.
- Dencatistat binds each monomerThe molecule mimics CTP and sits in all four CTPS1 subunits, with more than 1,000-fold selectivity over CTPS2.
- Proliferation stops, other cells are sparedWithout CTPS1 the T cells can no longer divide, while cells outside the blood system keep making CTP through CTPS2.
A first-in-class CTPS1 inhibitor
Lead asset dencatistat (STP938)
Step Pharma has unlocked the de novo pyrimidine synthesis pathway, a target that eluded cancer researchers for years.
Step Pharma has shown that cancers depend on CTPS1, and genomic loss of CTPS2 is a frequent event in cancer. That makes one oral, targeted drug relevant to blood cancers and to solid tumours.
Dencatistat is designed to kill cancer cells while sparing healthy cells, without the heavy side effects of many current and emerging therapies.
Read the CTPS1 sciencePipeline
Select a programme for trial detailsWhy a new approach is needed
Figures from step-ph.comfive-year survival in peripheral T cell lymphoma, unchanged in over 20 years
of all cancers may have lost CTPS2 and could benefit from selective CTPS1 inhibition
selectivity of dencatistat for human CTPS1 over CTPS2
For patients
Three open clinical studiesWe are bringing dencatistat to the patients who need it most, in blood cancers and solid tumours.
If you or someone you care for is living with essential thrombocythaemia, relapsed lymphoma or an advanced solid tumour, your doctor can check whether one of our studies is open near you.
Find our trials on ClinicalTrials.gov
Partnering, investment and clinical collaboration
Backed by a €38M Series C led by V-Bio Ventures and an EIC grant for CTPS2-null gynaecological cancers.
Talk to Step Pharma